CytRx concedes that its only drug flunked a PhIII sarcoma test, routing shares
Three years after one of its drugs had to be scrapped following a failed study, CytRx was forced to concede that its Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
